-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
3D Organoid Platform of InnoModels Biotechnology
Author:
InnoModels
Release time:
2024-08-30
In the continuous progress of biomedical research, the authenticity and reliability of in vitro models have become the focus of scientists' attention. Although traditional cell culture technology provides important support for drug discovery and disease research, its two-dimensional environment is difficult to fully simulate the complex physiological structure and function of the human body. InnoModels Biotechnology (Beijing) Co., Ltd. provides scientists with experimental tools that are closer to the real physiological environment with its cutting-edge 3D organoid platform technology, which greatly promotes the development of biomedical research.
Innovative advantages of 3D organoid platform:
Restore the real biological environment
The 3D organoid platform of InnoModels Biotechnology simulates the microenvironment of human organs by culturing cells in vitro and making them self-organize to form a three-dimensional structure. This technology can highly restore the physiological functions of organoids and make them closer to the biological characteristics of organs in the body. The platform supports the self-assembly of multiple cell types and can simulate complex organ structures, such as the liver, heart, lungs, etc., providing a wide range of application possibilities for research in different fields.
High-throughput experiments accelerate drug discovery
Compared with traditional 2D cell culture technology, 3D organoid platform not only provides a more realistic biological environment, but also supports high-throughput experiments. This feature allows drug screening and evaluation processes to be greatly accelerated, saving valuable time and resources for new drug discovery companies. InnoModels Biotechnology provides customized experimental solutions, adapting the technology to the specific needs of the research project to ensure that scientists are able to obtain the data that best meets their research goals.

Wide range of applications
InnoModels' 3D organoid platform has demonstrated its unique strengths in a number of areas. First, in the pre-screening and evaluation of drugs, the platform can provide more realistic and reliable in vitro models to accelerate the drug development process. Secondly, by restoring the physiological structure and function of organs, the toxicity of potential drugs or compounds can be assessed, providing a reliable basis for drug safety evaluation. In addition, using the 3D organoid platform to simulate the microenvironment of a specific disease, a more realistic disease model is established, which helps to study the disease mechanism in depth.
Technological Advantages of InnoModels Biotechnology
Co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and Shanghai Jiao Tong University Institute of Immunology, InnoModels Biotechnology (Beijing) Co., Ltd. has a stable domestic platform for humanized mouse models of the immune system (HIS) and a platform for humanized tumor xenografts (PDX). The company focuses on oncology and tumor immunopharmacodynamics CRO services, translational medicine research services and individualized medicine, and is committed to providing new generation of experimental animal models close to the clinic for new drug research and development enterprises, translational medicine researchers and tumor patients.
In-situ Experiment Platform
In addition to the 3D organoid platform, InnoModels Biotechnology is also committed to the development of the in situ experimental platform. The platform recreates the growth of a tumor in its natural environment by allowing the tumor to grow in its organ of origin, interacting with stromal cells and tissue-specific immune cells so that the tumor grows similarly to the development of the original tumor. In vivo imaging technology allows scientists to observe and monitor tumor growth and treatment response in real time, optimizing experimental design and drug treatment strategies.
Rich Experimental Experience and Expertise
With more than 5-10 years of experimental experience, InnoModels' experimentalists possess in-depth expertise and skills. Whether it is tumor growth and metastasis studies, drug screening and efficacy evaluation, or cell therapy and immunotherapy studies, the in situ experimental platform of InnoModels Biotechnology can meet the needs of scientists. Especially in brain in-situ experiments, the company has a complete blood-brain barrier experimental environment, which is helpful for researching therapeutic methods and drugs related to brain tumors.
Conclusion
With its unique advantages, 3D organoid platform of InnoModels Biotechnology shows great potential and value in the field of biomedical research. By providing more realistic and reliable in vitro models, the platform not only accelerates the drug development process, but also provides strong support for in-depth research on disease mechanisms. InnoModels Biotechnology will continue to be committed to promoting technological innovation in the field of life sciences, providing scientists with more advanced experimental tools, and jointly promoting the progress and development of biomedical research.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd